Federal Register #2026-13803

Licensing and Co-Development for Casq2 Mouse Strains and Liquid Biopsy Diagnostic for HPV 6/11 DNA

This opportunity from the National Institutes of Health (NIH), including the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Cancer Institute (NCI), seeks commercial partners for licensing and co-development of government-owned biomedical inventions. - Government Buyer: - National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) - National Cancer Institute (NCI) - Frederick National Laboratory for Cancer Research (FNLCR) - OEMs and Vendors: - No commercial OEMs or vendors are named; NIH, NCI, and FNLCR are the technology developers and licensors - Products/Services Requested: - Casq2Flox and Casq2RevFlox mouse strains (part number: E1282024) - Conditional and reverse conditional loss-of-function alleles in mouse Casq2 for research on catecholaminergic polymorphic ventricular tachycardia (CPVT) - Liquid biopsy diagnostic for circulating cell-free HPV 6 and 11 DNA (part number: E0192025) - Hybridization-based next-generation sequencing (NGS) method for non-invasive detection and monitoring of HPV 6 and 11 DNA in recurrent respiratory papillomatosis (RRP) patients - Unique or Notable Requirements: - Opportunity is for licensing and collaborative research, not direct product purchase - Focus on commercial development, integration into diagnostic platforms, and further validation - The liquid biopsy technology is pre-clinical and patent-protected (PCT/US2026/027273) - Mouse strains are intended as research tools for gene function and therapy studies - No specific purchase quantities or part numbers for services are listed

Description

The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) are seeking research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic. This diagnostic is a non-invasive method for detecting cell-free HPV 6 and 11 DNA in patients with recurrent respiratory papillomatosis (RRP), a disease caused by chronic HPV 6 or 11 infection. The method uses hybridization-based next-generation sequencing to detect circulating viral DNA, offering a sensitive and potentially prognostic tool for diagnosis, monitoring progression, and guiding systemic therapies. This technology aims to reduce the need for repetitive surgical interventions and improve disease management.

View original listing